Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin 
gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for 
the prophylaxis of migraine. In September 2021, atogepant was approved in the 
USA for the preventive treatment of episodic migraine in adults. The drug is 
also in phase 3 clinical development for the preventive treatment of migraine in 
various other countries. This article summarizes the milestones in the 
development of atogepant leading to this first approval for the preventive 
treatment of episodic migraine in adults.